Anthony Letai

45PUBLICATIONS
261CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumoursShip and platform structures (incl. maritime hydrodynamics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|May 26, 2026
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.

|Feb 19, 2026
What does BCL-2 do? From new molecular insights to the clinical implications.

Carlo M Croce, Stephen W G Tait, Ana J Garcia-Sáez

|Dec 26, 2025
Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Maria Davern, Cole J Turner, Daryl Griffin

|Jul 31, 2025
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.

Tayla B Heavican-Foral, Felix Korell, Irene Scarfò

|Jan 06, 2025
Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.

Julie A MacDonald, Gary A Bradshaw, Fleur Jochems

|Dec 20, 2024
Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.

Fleur Jochems, Chrysiida Baltira, Julie A MacDonald

Pageof 8

Frequent Collaborators

14 joint publications

Jeremy Ryan

4 joint publications

Patrick D Bhola

4 joint publications

Marcela V Maus

3 joint publications

Marlise R Luskin